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Abstract
Background: Adenocarcinomas (ACs) and squamous cell carcinomas (SCCs) differ by clinical and molecular characteristics.
We evaluated the characteristics of carcinogenesis by modeling the age patterns of incidence rates of ACs and SCCs of
various organs to test whether these characteristics differed between cancer subtypes.
Methodology/Principal Findings: Histotype-specific incidence rates of 14 ACs and 12 SCCs from the SEER Registry (1973–
2003) were analyzed by fitting several biologically motivated models to observed age patterns. A frailty model with the
Weibull baseline was applied to each age pattern to provide the best fit for the majority of cancers. For each cancer, model
parameters describing the underlying mechanisms of carcinogenesis including the number of stages occurring during an
individual’s life and leading to cancer (m-stages) were estimated. For sensitivity analysis, the age-period-cohort model was
incorporated into the carcinogenesis model to test the stability of the estimates. For the majority of studied cancers, the
numbers of m-stages were similar within each group (i.e., AC and SCC). When cancers of the same organs were compared
(i.e., lung, esophagus, and cervix uteri), the number of m-stages were more strongly associated with the AC/SCC subtype
than with the organ: 9.7960.09, 9.9360.19 and 8.8060.10 for lung, esophagus, and cervical ACs, compared to 11.4160.10,
12.8660.34 and 12.0160.51 for SCCs of the respective organs (p,0.05 between subtypes). Most SCCs had more than ten m-
stages while ACs had fewer than ten m-stages. The sensitivity analyses of the model parameters demonstrated the stability
of the obtained estimates.
Conclusions/Significance: A model containing parameters capable of representing the number of stages of cancer
development occurring during individual’s life was applied to the large population data on incidence of ACs and SCCs. The
model revealed that the number of m-stages differed by cancer subtype being more strongly associated with ACs/SCCs
histotype than with organ/site.
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Introduction
Multiple studies have demonstrated that adenocarcinomas
(ACs) and squamous cell carcinomas (SCCs) of the same organs
(such as lung, esophagus, and cervix uteri) differ by the role that
various risk factors play (e.g., smoking, body mass index and body
fat distribution, HPV subtypes, etc.) as well as by their clinical
presentations (e.g., patients with cervical and lung AC have poorer
prognoses, higher stromal invasion, metastasized more easily, and
are more resistant to radiotherapy than patients with cervical and
lung SCC) [1–12].On the molecular level, differences between
ACs and SCCs have been also observed. For example, more
genetic changes have been found to accumulate in SCCs, tumor
suppressor genes for these two subtypes are located on different
chromosomes, and ACs differed from SCCs by the levels of
expression of apoptosis inhibiting factor (i.e., survivin) and tumor-
invasion related factor (i.e., matrix metalloproteinase-2 and -7)
[13]. Based on similarity of age-incidence patterns identified on
logarithmically scaled plots, it has been suggested that tumors
which had common embryonic cellular ancestry, differentiation
pathways, and histologic characteristics may have similar charac-
teristics related to carcinogenesis processes even when arising from
different organs [14,15].
If similarities exist between ACs and SCCs in clinical and
molecular studies, then certain similarities within histotypes may
also exist for underlying mechanisms of carcinogenesis. For
example, when supposed that a population of cells must
experience a number of stochastic events (m-stages) in the path
toward a clinically diagnosed cancer, then the numbers of such
events may differ for ACs and SCCs. We hypothesized that certain
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37430similarities may exist between characteristics related to carcino-
genesis for ACs and for SCCs that could be even stronger than
organ-specific similarities. To test this hypothesis, we evaluated
tumor characteristics by applying a model to describe the age
patterns of incidence rates of ACs and SCCs across cancer sites
using the data from the large cancer registry. Our approach was
based on the idea that patients have to pass a certain number of
stages on their way to clinically diagnosed cancer. The current
understanding of these stages is more general than in the majority
of existing models of carcinogenesis, which assume sequential
mutations are the main driving forces of carcinogenesis. In our
model, the person (not the cell) has to pass from stage to stage; at
certain stages individual states can be associated with mutations in
susceptible cells. Rates of individual transitions between states are
not the same for all individuals. Instead, we assumed that these
rates were distributed in the population and parameters of this
distribution were the subjects for estimation. Variance in these
rates reflects variations in predisposition to certain cancers in
population. In this framework, the number of unobserved stages is
a model parameter (m-stages) that can be estimated by applying
the model to human population data on cancer incidence. Our
primary research task was to compare the estimates of m-stages for
ACs and SCCs across cancer sites and find some regularity in the
spectrum of found estimates. This modeling framework captures
the base features of carcinogenesis that correspond to the chosen
level of carcinogenesis simplification and allows for investigating
the research questions of interest. However, that was not the only
motivation of why this type of model was applied for analysis.
Another reason was that our preliminary analyses [16] showed
that this type of model provided a much better description of the
age patterns of the incidence rate for majority of cancers in the US
population up to the age of 85 years. In this paper, we demonstrate
the ability of the model to describe age-patterns of incidence across
a broad range of cancer sites. In spite of a good description of data
on cancer incidence by the model, the risk of model misspecifica-
tions needs to be controlled further by detailed sensitivity studies
that allow for testing for the stability of the results. The effects of
trends in the stage at diagnoses, gender and racial differences, and
age-period-cohort (APC) effects are incorporated into our base
model and are in focus of our sensitivity studies.
Materials and Methods
The age-adjusted incidence rates of fourteen ACs (lung,
esophagus, stomach, colon, rectum, pancreas, liver, breast ductal,
breast lobular, corpus uteri, cervix uteri, prostate, kidney, and
ovary) and twelve SCCs (lung, esophagus, cervix uteri, larynx,
anal, vulvar, lip, tongue, floor of mouth, gum and other mouth,
tonsil, and hypopharynx) were analyzed over a 31-year period
(1973–2003). The ACs and SCCs, which had more than 5,000
cases, were obtained from the list at the SEER Site Recode ICD-
O-2 (at http://seer.cancer.gov/siterecode/icdo2_d01272003) for
our defined time period (Table 1). For lung cancer, ACs (code 814)
and SCCs (code 807) were selected as the most prevalent among
those affecting the lung and having distinct clinical, pathological,
and molecular characteristics. Thyroid AC was excluded from this
analysis because of its numerous subtypes with unusual age
distributions. The frequencies of the specific stage at cancer
diagnosis (such as in situ, localized, regional, distant, and unstaged)
were analyzed to determine the possible contribution of these
changes to the characteristics of carcinogenesis for each studied
cancer. Comparisons of age patterns of incidence for studied
cancers diagnosed at all stages jointly and for invasive cancers
alone were also performed.
The age patterns of incidence rates for the fourteen ACs and
twelve SCCs were studied for quality of fit for various models. We
considered the one-year age interval for age-specific incidence
rates. Two-stage modeling approach was applied for the spectrum
of these age patterns. Analysis at the first stage was designed to
select the best model by applying the known carcinogenesis models
to sex-, race-, and year-specific age patterns. At the second stage,
the best model for ACs and SCCs was generalized to analyze the
data independent of sex-, race- and year-specificity.
To diminish the effects of advances in screening and diagnostics,
we analyzed cancer incidence rates for three periods (1973–1983,
1984–1993, and 1994–2003) (see Table S1). The classic Armitage-
Doll model [17], the two-stage clonal expansion (TSCE) model,
and several types of the models with hidden frailty were tested.
Our analysis confirmed the conclusions made by evaluating the
quality of fit of each model to all sex-, race-, and time period
specific age-patterns of ACs and SCCs using x
2 and Fisher’s
criteria, that the frailty model with the Weibull baseline with the
frailty described by a family of distributions (gamma or inverse
Gaussian) provided the best fit for majority of cancers [16]. First,
we applied this approach to an extended set of race-sex-time
period-specific analyses of 264 age patterns of cancer incidence
(Table S1). The analytic expression of the model for incidence rate
is:
I0(x)~
xm{1
cm 1zns2c{mm{1xm ðÞ
1=n , (1)
where: x is the age at cancer diagnosis, m (m-stages) is the number
of stages occurring during the person’s life and leading to cancer
development, c (in years) is the parameter related to the maximum
age in the cancer incidence age pattern, s2 is the variance of the
frailty distribution that reflects an individual susceptibility to
cancer risk, and n describes the shape of the frailty distribution
(n~1, 2, and 0 corresponds to gamma-distribution, inverse
Gaussian distribution, and the distribution suggested in Manton
et al. [18] respectively). For nƒ1, the shape of the age-pattern
represented by the model has a maximum with age equal to
cm (m{1)(nzm{mn)
{1s{2  1=m
: In our model, the term ‘‘m-
stages’’ describes the number of ‘‘malignant’’ rate-limiting events
that a person had on the way of to the occurrence of malignant
tumor (the ‘‘m’’ was added before ‘‘stages’’ to distinguish from the
‘‘stages at diagnosis’’); thus, the meaning of m-stages here does not
correspond exactly to one from a classic work of Armitage-Doll
[17] or from other models of carcinogenesis such as MVK [19,20]
and TSCE [19,20]. Our goal was to compare all cancers
simultaneously to test the general hypothesis about the differences
between ACs and SCCs. To do so, we adopted a parsimonious
style of modeling that resulted in minimal number of weakly
correlated parameters.
For each cancer, the minimum age of cancer incidence patterns
to be analyzed was selected based on the results of empirical
analysis of the maximum age at which there were no cancer cases
recorded in the SEER registry. The minimum age estimate was 30
years for cancers of lung, stomach, esophagus, colon, rectum,
pancreas, liver, kidney, breast lobular, corpus uteri, and cervical
AC, and 15 years for SCCs of cervix, anus, vulva, and head and
neck. The highest minimal age was for patients diagnosed with
prostate cancer (40 years old).
At the first stage of analysis, age-specific cancer rates were
evaluated with the standard errors and age patterns were fitted by
the model (1). For example, for patients with lung ACs, 55 age-
specific rates (from ages 30 to 84 years old) were used. At the
second stage, the model was generalized to analyze age-, year-,
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37430Table 1. The frequencies of stages at cancer diagnosis in the SEER Registry, 1973–2003, in percent. (Initial, final, and years of
significant changes – if needed - in stages distribution are presented).
Cancer Site (code) Year In situ Localized Regional Distant Unstaged
Lung SCC (807) 1983
1 0.4 20.9 40.7 24.1 14.0
2003 0.3 24.6 46.5 24.1 4.5
Lung AC (814) 1983
1 – 20.4 34.4 37.2 8
2003 – 19.5 38.0 38.8 3.7
Stomach AC (814, 849) 1973 0.3 15.9 33.1 32.6 18.2
2003 0.9 22.0 33.0 34.5 9.6
Esophagus SCC (807) 1973 0.2 27.6 20.9 22.6 28.6
2003 0.8 23.5 33.0 26.2 16.5
Esophagus AC (814) 1973 – 12.5 22.5 47.5 17.5
2003 2 23.7 30.5 31.6 12.1
Colon AC (814, 826, 848, 801, 821) 1973 2.5 27.5 31.8 20.8 17.4
2003 6.2 38.0 34.8 17.6 3.4
Rectum AC (814, 826, 848, 821) 1973 4 37.6 26.1 15.7 16.6
2003 6.9 43.3 30.3 14.0 5.5
Pancreas AC (814, 801, 848) 1973 – 11.3 17.2 44.6 26.9
2003 0.1 7.1 26.6 55.0 11.3
Liver AC (817, 801, 814) 1973 – 13.9 15.7 33.4 36.9
2003 – 40.7 25.4 18.0 15.9
Kidney AC (814, 831) 1973 – 40.4 17.9 27.8 13.8
2003 0.1 62.6 15.3 18.4 3.7
Breast AC (850) 1973 4.5 39.1 40.3 4.0 12.1
1996 16.3 54.9 24.1 3.2 1.5
2003 19 50.6 26.2 3.3 1.0
Breast AC (852) 1973 26.4 32.8 25.6 4.2 10.9
2003 18 47.6 29.5 4.2 0.8
Prostate AC (814) 1983
1 – 75.0 17.9 7.0
2003 – 94.0 3.4 2.6
Ovarian AC (814, 826, 838, 844, 846, 847) 1973 – 24.6 7.7 54.5 13.2
2003 0.4 14.5 6.6 76.6 2.0
Corpus uteri AC (814, 838) 1973 7.3 69.7 3.9 3.7 15.4
2003 1.5 74.3 15.8 4.8 3.7
Cervix uteri AC (814) 1973 2.4 44.7 24.7 8.2 20.0
1995 55.2 31.4 7.6 1.5 4.1
1996 – 62.7 22.3 7.7 7.3
2003 – 62.4 22.0 8.7 6.9
Cervix uteri SCC (807) 1973 63.2 19.6 9.5 2.5 5.2
1995 88.2 6.2 4.1 0.7 0.8
1996 – 52.1 36.3 6.6 5.0
2003 – 47.3 40.1 9.3 3.3
Larynx SCC (807) 1973 3 52.9 25.3 3.0 12.5
2003 5.9 41.5 46.5 3.5 2.6
Anal SCC (807) 1973 6.4 46.8 31.9 4.3 10.6
2003 29.2 36.3 22.4 6.9 5.2
Vulvar SCC (807) 1973 20.5 43.9 19.7 1.5 14.4
2003 63.5 20.8 10.8 1.3 1.8
Lip SCC (807) 1973 1.4 65.5 7.4 0.8 24.9
2003 6.6 75.3 12.6 1.1 4.4
Tongue SCC (807) 1973 1.0 32.8 36.1 11.7 18.4
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SCCs). For example, for lung AC, a total of 6820 patterns were
fitted: i.e., 55 patterns [for 55 age-specific groups] x 31 patterns
[for 31 years] x 2 patterns [for males and females] x 2 patterns [for
Caucasians and African-Americans]. The generalized model is:
I(x)~RIsex
sex RIrace
race 1z0:01:Fyear
 Y{2000
10
xm{1
cm 1zns2c{mm{1xm ðÞ
1=n
ð2Þ
where Rsex and Rraceare relative risks of increased cancer
incidence for females and for African-Americans, respectively
(Isex~1 for female and 0 for male, and Irace~1 for African-
Americans and 0 for Caucasians); Y is a calendar year, and Fyear is
related to the percent change in incidence rates for a 10-year
period. Parameters were estimated using nonlinear regression,
with weights reciprocal to the variance estimated using the
generalized Wilson’s approach [21]. The accuracy of the
description of AC and SCC-specific incidence age patterns was
evaluated by the value of x2/d.o.f and by analysis of residuals for
each fit for normality, heteroscedasticity, and autocorrelation
(using SAS, SAS Institute; Cary, NC, Proc Model).
This analytic approach permitted the use of all ages within the
SEER registry in the analysis, including ages above 80 years old,
where decrease of cancer incidence rates is observed for majority
of cancers. Decreasing cancer incidence rates at advanced ages
must be appropriately reflected in the successful carcinogenesis
model; this phenomenon often cannot be handles by the models of
this class (e.g., TSCE) or remains ignored by researchers [22]. The
most popular explanation of the decline in incident rates at
advanced ages is that it is caused by the hidden heterogeneity in
individual predisposition to cancer. The potential sources of such
heterogeneity include the different stages of diagnosed cancer with
likely different shapes of incidence rates, different sub-histological
forms of cancer, different race effects and effects of genetic
predisposition, different contributions of environmental exposure,
and different effects of cohort, period, or both due to time trends
coming from the progress in medical technologies, screening, and
variety of clinical interventions (see also discussion by Yashin et al.
[23]). While these sources of heterogeneity in an individual
predisposition to cancer can be taken into account using available
data (i.e., racial, gender, and cohort/period effects), the majority
(e.g., genetic effects or environmental exposure) have to be
modeled stochastically. Our modeling strategy involved explicit
modeling of the effects of the first type using available data and
stochastic modeling of the second type effects. In particular, the
stochastic model involves two parameters to represent a distribu-
tion of the individual predisposition remaining after explicit
inclusion of the effects of first type. These parameters are s2 and n.
In model (2), racial, gender, and period effects were explicitly
modeled. Because of parsimonious style of modeling, only one
parameter is responsible for reflecting a period effect. Since it can
be not sufficient to represent the variety of period/cohort effects,
in sensitivity studies we applied age-period-cohort (APC) modeling
as incorporated into carcinogenesis model according Moolgavkar
et al. [24]. In this approach, period and cohort effects are
represented non-parametrically. Specifically, the APC model
linked to carcinogenesis model (2) is obtained by a substitution
1z0:01:Fyear
 Y{2000
10 ?acohaper; ð3Þ
where cohort- and period-specific parameters acoh and aper are
subject for estimation.
Results
We applied mathematical models (1) and (2) to the SEER
dataset. Model (1) was applied for sex-, race-, and decade-specific
data (see Table S1). The main parameters characterizing
carcinogenesis, including the number of m-stages (m), the age of
maximal risk of cancer incidence (c), standard deviation of frailty
distribution (s), and the shape of the frailty distribution (n), did not
vary substantially for most of the cancer sites by time period, sex,
or race. There were, however, some visible trends for certain
cancers. For example, there was a tendency for m-stages to
decrease with time for cancers of head/neck, esophagus SCC,
stomach, rectum, breast lobular, and prostate, and increase for
lung SCCs. Males had slightly more m-stages than females for
cancers of the stomach, colon, kidney, and tongue. Caucasians
males with pancreatic cancer had slightly more m-stages than
African-American males and slightly fewer m-stages in patients
with laryngeal and tongue cancers. Caucasian females with rectal
cancer had slightly fewer m-stages than African-American females.
The majority of cancers had good model fit based on the x2/d.o.f
value, however, for prostate AC and cervical SCC x2/d.o.f values
Table 1. Cont.
Cancer Site (code) Year In situ Localized Regional Distant Unstaged
2003 2.8 34.4 49.1 10.7 2.9
Floor of mouth SCC (807) 1973 1.6 29.5 41.0 8.2 19.7
2003 6.2 38.1 46.0 5.2 4.5
Gum and other mouth SCC (807) 1973 1.2 35.6 36.4 10.7 16.2
2003 3.8 34.3 49.7 6.2 6.0
Tonsil SCC (807) 1973 2.3 15.4 46.3 21.7 14.3
2003 1.0 12.8 73.1 10.3 2.8
Hypopharynx SCC (807) 1973 – 17.1 40.3 27.1 15.5
2003 0.8 11.6 66.9 17.2 3.4
Notes: * Only for prostate cancer (1983–2003 all localized and regional cases coded as ‘‘Localized/regional Prostate cases’’.
1– Data on stages prevalence are available
since 1983.
doi:10.1371/journal.pone.0037430.t001
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Among all the studied cancers, model (1) had a good fit with
incidence patterns for a majority of AC and SCC; the fit was less
precise for breast, cervical, and vulvar cancers (Figure 1). This
discrepancy can be attributed to latent heterogeneity in these
cancers that was not captured by the simple approach based on
distributed frailty. For example, tumor grades and estrogen/
progesterone receptor status can provide additional and significant
contributions to such heterogeneity [25].
The number of m-stages determined using model (1) was the
parameter of principal interest in this study (Table 2). There were
no significant differences in the number of m-stages within either
the ACs or within the SCCs groups. When cancers of the same
organs were compared (i.e., ACs and SCCs of the lung, esophagus,
and cervix uteri), the number of m-stages was similar within ACs
(lung 9.7960.09, esophagus 9.9360.19, and cervical 8.8060.10)
and within SCCs (11.4160.10, 12.8660.34 and 12.0160.51,
respectively); the number of m-stages was greater for SCCs than
for ACCs (p,0.05). This suggests that ACs and SCCs may require
different numbers of events for cancer development. In general,
SCCs appeared to require more m-stages for their development
than ACs (Figure 2). Most SCCs had more than ten m-stages and
ACs had fewer than ten m-stages, except for prostate and breast
lobular cancers. The latter, probably, have two ‘‘forms’’–younger’’
and ‘‘older’’–that differ by patient’s age at manifestation,
aggressiveness, response to treatment, and relation to sex hormone
exposure. Recently, some of the contributing to such forms factors
were studied for mechanisms of breast carcinogenesis [25].
To take into account the possible effects of sex, race, and time
period, we included Rsex, Rrace and Fyear parameters in a generalized
model (2) (Table 2). The differences in parameters c and s
between cancers reflect the diversity of the respective incidence
rates. Parameter cis the age dimension that characterizes the age
at the cancer’s maximal incidence rate (existing for nƒ1), and s
characterizes the shape of the distribution of predisposition to
cancer in population (for distributions with large estimated values
of s
, the shape is largely concave, i.e., most individuals have a low
predisposition, and the rest of the population is widely distributed).
Parameters Rsex and Rrace describe the relative risks of cancer
incidence in females and in the African-American population,
respectively. The strongest effect of sex (Rsex#0.30 in Table 2) was
for cancers of the lung (SCC), esophagus (SCC and AC), liver,
larynx, lip, floor of mouth, tonsil, and hypopharynx, while the
strongest effect of race (Rrace#0.30 in Table 2) was for esophageal
AC, cervical AC, and cancers of ovary, corpus uteri, and lip, and
for esophageal SCC (Rrace=2.75). ParameterFyear characterizes the
percent change in incidence rate for a 10-year period in
accordance with the results of empirical analysis of incidence
trends: cancers of esophagus (AC), liver, breast lobular, cervix uteri
(SCC), anal, and vulvar had the strongest effects of this parameter
(absolute value of Fyear$50%). The estimated values of x2/d.o.f
showed that the fit was improved when compared to the model (1)
(see Table 2 and Supplemental Table S1).
Sensitivity analyses of the model parameters demonstrated the
stability of the obtained estimates. Model parameters were not
sensitive to a) the choice of the initial/minimal age at cancer
diagnosis and inclusion/exclusion of the age group 85+ years old;
b) the addition of a quadratic term describing time trends; c) the
specific stratification of population groups (e.g., 5-year age
interval); d) an estimation using the maximal likelihood approach
rather the non-linear least squares; and e) considering specific time
periods or stratifying population according to sex and race (Table
S1). Also, the results did not significantly change when applying
the APC to our model. For example, significant differences
remained between numbers of m-stages for ACs and SCCs: for
ACs and SCCs of the lung (8.9060.13 and 9.8460.13, p,0.05),
esophagus (11.4360.31 and 13.9860.57, p,0.05), and cervical
uteri (8.4261.38 and 12.1260.28, p,0.05), respectively. For the
majority of cancers, parameters of the model did not change after
incorporating the APC into the model; and the m-stage parameter
was stable for all cancer sites. For some cancers (lung SCC,
esophageal AC, breast lobular, and prostate) the estimated
averaged numbers of m-stages shifted for about 1.5 stages, and
for anal cancer it shifted even more. However, the direction of
these shifts did not correlate with histotype (i.e., with ACs/SCCs
tumor type).
Several interesting effects were observed during analysis of
cohort- and period-specific parameters (i.e., acoh and aper in Eq.
(3)). For several cancers where birth cohort effects were observed,
four different shapes of acoh were evident: 1) increasing effect in
older cohorts–for lung SCC and breast ductal carcinomas; 2)
increasing effect in younger cohorts–for liver, breast lobular, and
cervical SCC; 3) increasing effects till 1930–1939 birth cohort with
subsequent decrease–for ACs of lung and corpus uteri; and 4)
slightly decreasing effects for older cohorts with subsequent
increase beginning from 1940–1949 birth cohort–for prostate
cancer. The following calendar period effects represented by aper
were also observed: 1) increasing with time effects–for ACs of lung,
esophagus, liver, breast (both types), and kidney, and for anal,
vulvar, tongue, and tonsil SCCs; 2) decreasing with time effects–
for colon AC, and SCCs of lung and lip; 3) effects peaked around
1991–1995 years–for prostate AC and cervical SCC (likely, due to
the introduction of active screening strategies at this time). In total,
the results obtained from the main model demonstrated good
stability after implementing the APC into the model.
Discussion
In this study, the characteristics of carcinogenesis were analyzed
across cancer sites and certain similarities were found inside cancer
subtypes: adenocarcinomas (ACs) and squamous cell carcinomas
(SCCs) likely require different numbers of stages for cancer
development, with more m-stages required for SCCs than for ACs.
In general, the obtained results confirmed out the hypothesis that
characteristics of carcinogenesis may be more specific to cancer
subtype (ACs or SCCs) than the organ/site. These results are
consistent with other studies suggesting that oncogenesis could
potentially be more informative when applied to distinct cancer
subtypes rather than organs because their progression pathways
may differ [15,26,27].
The results obtained in our study are also in agreement with
multiple clinical observations on ACs and SCCs. For example,
when ACs and SCCs of the same organs were compared (such as
of lung, cervix uteri, esophagus, and gallbladder), patients with
ACs had poorer prognosis and higher metastatic rates, and were
more resistant to radiotherapy than patients with SCCs [4–
6,28,29]. Effectiveness of chemotherapy were shown to differ for
ACs and SCCs: e.g., a docetaxel (an anti-mitotic chemotherapy
medication) was more effective in treatment of lung SCCs, while a
pemetrexed (an antifolate antineoplastic agent) was more effective
Figure 1. The results of model fitting for ACs/SCCs for each cancer site. (Rates for different cancers are rescaled to use the same scale on all
plots for comparison. The original rate can be calculated by dividing the values obtained from the plot to the rescaled factor).
doi:10.1371/journal.pone.0037430.g001
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and their prognostics values have been identified for lung and
cervical SCCs (such as higher expression of epidermal growth
factor receptor, cyclin B1, p53, and COX-2) when compared with
ACs (that had a higher expression of c-myc) [31–33]. Also, an
increased expression of the embryonic stem cell gene set that is
associated with poor survival has been observed for lung ACs but
not for SCCs [34]. Altogether, these results affirm the differences
in certain clinical characteristics and diagnostic markers between
SCCs and ACs and agree with our findings that such differences
could be more pronounced between histotypes than between
tumors of different organs. Differences in characteristics of ACs
and SCCs could be also illustrated (indirectly) by the studies on
multiple primary cancers. Such studies demonstrate the frequent
co-existence (at the same time or at separate times) of cancers of
the same type (ACs or SCCs) at different locations in the same
individual: e.g., for SCCs of the oral cavity and pharynx and
esophagus, or of lip and skin; for ACs of the breast and ovary and
corpus uteri, or of the prostate and urinary bladder, or of colon
and rectum [35–37].
While our model was able to reveal the differences between ACs
and SCCs, it could be capable to describe the differences between
solid cancers (such as ACs and SCCs) and non-solid malignancies.
We applied our model to the age patterns of incidence of leukemia
and non-Hodgkin’s lymphoma from the SEER Registry data. It
showed that leukemia (5.2460.07) and non-Hodgkin’s lymphoma
(4.2960.04) had fewer m-stages than solid cancers such as ACs
(7.8–9.8) and SCCs (10.2–13.8). The obtained results were in
agreement with studies of other researchers that demonstrated that
non-solid malignancies likely required fewer stochastic events/
stages for their development than solid cancers [38,39]. The latter
often have pre-malignant lesions long before cancer is clinically
diagnosed thus allowing us to hypothesize that some occult stages
of solid cancer development result in larger number of stages
occurring in individual.
The results obtained from our model showed that certain ACs
such as lobular carcinoma of the breast or prostate cancer had
more stages on average than the rest of ACs. When compared with
other studies, our results were in agreement with their results
demonstrating the differences, for example, between breast cancer
and several other ACs: i.e., breast cancer differed in its somatic
mutation spectrum from ACs of colon, rectum and pancreas
leading to the conclusion that breast epithelial cells might be
exposed to different levels or types of carcinogens or use distinctive
repair systems [40,41].
From the methodological point of view, our approach can be
viewed in a historical perspective of developing carcinogenesis
models that were applied to the age patterns of incidences of
various cancers. It is still the subject for scientific debate on how to
make a precise model and what kind of information could be
obtained from them [42]. Armitage and Doll first demonstrated
that age-mortality [17] and, later, age-incidence [43] patterns of
certain epithelial cancers could be related to the number of cellular
events (such as mutations) involved in the formation of a malignant
tumor. Developed later by Moolgavkar and Knudson [44], and
Tan [45] two-stage clonal expansion (TSCE) model and other
multistage clonal expansion (MSCE) models, have different
biological interpretations of the equivalent of the stages: e.g., in
the TSCE model this parameter is closely related to promotion of
pre-malignant cells. The understanding of m-stages in our model
are not completely relevant to those above, as well as to those from
the later generalizations of TSCE model capable for accounting
for many sequential rounds of clonal expansion at different growth
rates [46,47]. Being a population-based, our model considers a
person at a certain m-stage progressing to cancer onset. Transition
of an individual from one m-stage to the next could be interpreted
as a generalized ‘‘carcinogenic event’’ that occurred at a certain
rate mathematically related to model parameters: i.e., parameter c
is related to averaged transition rate between m-stages, and
parameters of frailty distribution (n and s) describe the distribution
of this rate in population. The cancer-specific number of m-stages
can be estimated as one of the model parameters allowing for
comparison of m-stages among cancer site and their ACs/SCCs
type. The transitions between m-stages in our model can be
associated with mutations, adverse epigenetic or stromal events.
However, the number of m-stages in our analysis is not fully
corresponding to the number of oncogenic/molecular changes
because several carcinogenic molecular changes could occur
within the same m-stage [48]. Different molecular analyses
suggested different numbers–from four to seven–of oncogenic
molecular changes that may feature on colon cancer and at least
ten–for prostate cancer [20,46,49–51]. Recent studies demon-
strated that ACs and SCCs could differ by the involvement of
different anti-cancer barriers. For example, the inhibition of
apoptosis plays more important role in cervical ACs, while tumor-
invasion related factors are more important for cervical SCCs
[52]. To include molecular mechanisms in our carcinogenesis
model, the concept of barrier mechanisms that was recently
developed for non-solid malignancies could be further incorpo-
rated in our model for solid cancers. Since the state of anti-cancer
barrier systems can be measured in molecular analyses, this
approach has the potential to be a bridge between epidemiology
and molecular biology [53–55].
It is interesting to compare the results of our study with another
study that used the same SEER Registry data and analyzed the
factors underlying the differences between the obtained results.
Recently, Rieker et al [22] described multi-step models for two
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Figure 2. The estimated numbers of m-stages with respective
standard errors (SE) for ACs (black dots) and SCCs (circles).
Note: breast 850 – breast duct carcinoma, breast 852 – breast lobular
carcinoma.
doi:10.1371/journal.pone.0037430.g002
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oropharyngeal) using SEER data: the expected number of stages
needed for cancer development was higher in ACs (about 10–11
for colorectal and about 23 for prostate cancer) than in SCCs
(approximately about 5–6 for oropharyngeal and 7–8 for laryngeal
cancers). Rieker et al [22] used the standard two-parameter
multistage carcinogenesis model for a homogeneous population
and applied a different approach for parameter estimation. The
focus of our update in the base model generalization was on the
quality of fit of age patterns of cancer incidence, especially at the
region of middle and advanced ages (see Figure 2). In this region
(75+ years) cancers occur at a higher rate and, probably, with
rapid cancer rate growth, therefore this region is the most
responsible for the precise estimation of the number of m-stages.
The model used by Rieker et al [22] was not able to adequately
describe the incidence in this region resulting in possible distortion
in estimates of the number of m-stages. Our model is reduced to
the model used by Rieker et al., if to set s~0 in model (1). Even in
this approximation and within age region restricted by age 75, we
cannot confirm their results that SCCs required lower numbers of
events than ACs: e.g., our estimates show that m-stages for SCCs
lung and esophagus were higher than respective estimates for ACs.
The existence of the ‘‘older ages’’ phenomenon has been
confirmed by numerous demographic and epidemiological data
indicating that cancer incidence (as well as cancer mortality) for
most of cancers increases at a slower rate with age, leveling off
around the age of 85–90 years old, and thereafter reaching a
plateau and even a decline [56–62]. It likely mirrors one of the
important breakthroughs of demography in recent years, i.e.
leveling-off of the rate of oldest-old mortality rate and deviation of
mortality rate from the Gompertz curve [59]. The modeling
approach used in our study suggests that the observed decrease of
cancer incidence at older ages could be explained by the
phenomenon of ‘‘selection’’: i.e., when different age groups have
different susceptibility to carcinogens exposure, or different repair
systems, or both. The heterogeneity in susceptibility is modeled by
a frailty distribution and parameters of the distribution are
estimated by applying the model to the data on incidence rates.
While interpreting the results obtained in our study, one should
understand that these results could be true only if there were no
other measured or latent variable(s) that could also impact the total
and ACs/SCCs-specific distributions of m-stages. For example, the
stage at cancer diagnosis could potentially be such a variable. To
test the alternative hypothesis that the stage at diagnosis could
affect the number of m-stages, correlations between the fractions of
in situ and distant stages and the number of m-stages were
examined. While no correlations were found when ACs and SCCs
were analyzed jointly, correlations were detected in histotype-
specific analysis. For example, the correlation between m-stages
and the distant stages of cancer was r=0.45 (p=0.14) for twelve
studied SCCs, and r=0.47 (p=0.17) for nine ACs originated from
non-reproductive organs (i.e., excluding breast, ovarian, cervical,
and prostate ACs). In pooled analysis (i.e., not ACs/SCCs-specific)
this correlation disappeared (r=0.05, p=0.82). Histotype-specific
means of m-stage parameter were 10.560.6 for SCCs and 9.360.5
for ACs, as well as 9.060.3 for ACs originated from non-
reproductive organs, while the respective means of distant
fractions were 10.562.7%, 25.265.6% and 27.165.5%, respec-
tively. So, ACs had even higher fraction of advanced cancer stages,
but still had significantly lower number of m-stages than SCCs.
Therefore, the differences in distribution of stages at cancer
diagnosis cannot explain the results presented in Figure 2. The
frequency of unstaged cancers differs among cancer sites and that
might be an issue that should be taken into account [63]. To check
that, we compared estimated correlations between the number of
m-stages and distant cancer stages and correlations calculated with
added distant cases ‘‘hidden’’ among unstaged cases (assuming
that the distribution of unobserved stages among the unstaged
cancers was the same as the distribution of staged cancer cases for
each studied year). The correlations with and without added
contribution of unstaged cancers were found to be almost
identical.
Certain behavioral risk factors can potentially affect some of the
characteristics of carcinogenesis. However, most of population-
based large datasets lack of the information on individual-based
exposure to such factors. The stochastic approach in our model,
which reflects hidden heterogeneity, can describe the effects of
behavior factors (i.e., smoking) on predisposition/susceptibility to
cancer. The exposure to such factors is one of the sources of
heterogeneity modeled by the frailty distribution, i.e., parameters n
and s need to capture such exposure and possible their changes
have to be responsible for exposure dynamics. For certain cancers
the number of m-stages may change when certain risk factor(s)
becomes more prevalent in population with time. Unfortunately,
SEER registry does not provide the information on smoking and
the direct study on such effects cannot be performed using this
dataset. However, applying the APC analysis to our model allows
indirect evaluation of smoking impact through the birth-cohort
effect. Several studies adapted the TSCE model of lung
carcinogenesis for a given smoking cohort and showed different
effects of tobacco on cancer initiation and promotions [64,65]. In
our study, an increase for about two m-stages was observed from
1973–1983 to 1994–2003 for lung SCCs (but not for lung ACs) in
females (see Table S1). This increase in the number of m-stages
may be due, in part, to the change in cigarette composition over
the three decades with decreased tar and nicotine coupled with the
increased use of expanded and reconstituted tobacco with higher
amount of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone which
may require more exposure-related events for developing of the
lung SCC.
Study limitations. Because the estimation of carcinogenesis
characteristics obtained within our model assumed carcinogenesis
to be a multistage process, a dependence on this assumption is a
limitation. However, we reviewed and tested a spectrum of
different models of carcinogenesis based on different assumptions
and found that the chosen model adequately described the age
patterns of incidence rates (Figure 1). That was confirmed in a
sensitivity analysis. Several model assumptions can be considered
as limiting factors. The assumption about population homogeneity
for carcinogenesis parameters m and c is typical for all
compartmental models. In our analyses, certain cancers could be
described with a better fit using a mixed model (such as two-
disease models with different model parameters for two population
subgroups). The underlying heterogeneity in these groups could
not be captured in the current study by simple AC/SCC grouping.
An inclusion of further tumor classifications (such as grade-specific,
receptor-specific, and molecular pathway-specific) could decrease
tumor heterogeneity, allowing a simpler one-disease model to be
applied to each subgroup. Another concern is the stage at
diagnosis, which was not explicitly incorporated into the model:
our modeling approach was applied for cancer cases without
stratification by stage at diagnosis. However, correlations between
the fractions of in situ, distant, and distant plus unstaged stages and
number of m-stages were studied. Our approach permits using our
model parameters to compare similarities or differences in the
underlying mechanisms of both common and rare cancers. For
rare cancers, the model could be improved in future research by
the fixation of certain parameters using auxiliary information from
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other models of carcinogenesis, does not provide explicit biological
interpretations of m-stages, the obtained results have to be carefully
interpreted. Also, the lack of exposure information in SEER
Registry data (such as cigarette smoking in relation to lung cancer)
limits the modeling effort and requires further validation on
datasets where information on specific exposures is available.
In summary, a model capable of representing the average
number of stochastic events (which we denoted m-stages) occurring
in cells during the person’s life was developed and validated using
a large population dataset on cancer incidence. The numbers of m-
stages in the model were estimated for fourteen ACs and twelve
SCCs. It was found that ACs and SCCs may require different
numbers of events for cancer development that may be more
specific to subtype (AC, SCC) than the organ/site. The obtained
results allow for developing the biomedical interpretations of this
phenomenon and formulate new hypotheses that will be important
for basic medical science and broad clinical applications.
Supporting Information
Table S1 Modeling results (i.e. fitting parameters with
SE) for selected cancer histotypes model fitting, for male
and female white and African-American (AAs) U.S.
population for three time periods: 1973–1983, 1984–
1993, and 1994–2003.
(DOC)
Acknowledgments
The authors thank Fred and Alice Stanback for supporting this study with
a philanthropic donation to the Duke Comprehensive Cancer Center. The
authors acknowledge Donald T. Kirkendall, PhD, ELS for his assistance in
manuscript preparation.
Author Contributions
Conceived and designed the experiments: JK IA. Performed the
experiments: JK IA. Analyzed the data: JK IA. Contributed reagents/
materials/analysis tools: APA HKL. Wrote the paper: JK IA APA HKL.
Provide input in model development: APA HKL.
References
1. Coy P, Elwood J, Coldman A (1981) Clinical indicators of prognosis in
unresected lung cancer. Chest 80: 453.
2. Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, et al. (1984) Prognostic
factors in patients with resected stage I non small cell lung cancer. A report from
the Lung Cancer Study Group. Cancer 54: 1802–1813.
3. Rosenthal SA, Curran WJ (1990) The significance of histology in non-small cell
lung cancer. Cancer Treatment Reviews 17: 409–425.
4. Janssen-Heijnen ML, Coebergh JW (2001) Trends in incidence and prognosis of
the histological subtypes of lung cancer in North America, Australia, New
Zealand and Europe. Lung Cancer 31: 123–137.
5. Blot WJ MJ, Fraumeni JF Jr. (2006) Esophageal Cancer. In: Schottenfeld D FJ,
Jr, eds. Cancer Epidemiology and Prevention. Oxford: University Press. pp
697–706.
6. Schiffman MH HA (2006) Cervical Cancer. In: Schottenfeld D FJ, Jr, eds.
Cancer Epidemiology and Prevention. Oxford: University Press. pp 1044–1067.
7. Boffetta P, Trichopoulos D (2002) Cancer of the lung, larynx, and pleura. In:
Adami H-O, Hunter D, Trichopoulos D, eds. Textbook of cancer epidemiology.
Oxford: University Press. pp 248–280.
8. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, et al. (2007)
Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer
Research 67: 2345–2350.
9. Thune I, Lund E (1997) The influence of physical activity on lung-cancer risk - A
prospective study of 81,516 men and women. International Journal of Cancer
70: 57–62.
10. Lagergren J, Bergstro ¨m R, Nyre ´n O (1999) Association between body mass and
adenocarcinoma of the esophagus and gastric cardia. Annals of Internal
Medicine 130: 883.
11. Green J, Berrington de Gonzalez A, Sweetland S, Beral V, Chilvers C, et al.
(2003) Risk factors for adenocarcinoma and squamous cell carcinoma of the
cervix in women aged 20–44 years: the UK National Case-Control Study of
Cervical Cancer. British Journal of Cancer 89: 2078–2086.
12. Yoshida H, Sumi T, Hyun Y, Nakagawa E, Hattori K, et al. (2003) Expression
of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell
carcinoma of the uterine cervix. Oncology Reports 10: 45–49.
13. Sato S, Nakamura Y, Tsuchiya E (1994) Difference of allelotype between
squamous cell carcinoma and adenocarcinoma of the lung. Cancer Research 54:
5652.
14. Pierce DA, Mendelsohn ML (1999) A model for radiation-related cancer
suggested by atomic bomb survivor data. Radiation Research 152: 642–654.
15. Henson DE, Schwartz AM, Nsouli H, Albores-Saavedra J (2009) Carcinomas of
the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a
field for carcinogenesis: a population-based study. Archives of Pathology and
Laboratory Medicine 133: 67–71.
16. Manton K, Akushevich I, Kravchenko J (2009) Cancer Mortality and Morbidity
Patterns in the U.S. population: An Interdisciplinary Approach; Gail M,
Krickeberg, K., Samet, J., Tsiatis, A., Wong, W., editor. New York, NY:
Springer.
17. Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage
theory of carcinogenesis. British Journal of Cancer 8: 1.
18. Manton K, Akushevich I, Kulminski A (2008) Human Mortality at Extreme
Ages: Data from the NLTCS and Linked Medicare Records. Mathematical
Population Studies 15: 137–159.
19. Moolgavkar SH (1988) Biologically motivated two-stage model for cancer risk
assessment. Toxicology Letters 43: 139–150.
20. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nature Reviews
Cancer 1: 157–162.
21. Brown LD, Cai TT, DasGupta A (2001) Interval estimation for a binomial
proportion. Statistical Science 16: 101–133.
22. Rieker RJ, Hoegel J, Kern MA, Steger C, Aulmann S, et al. (2008) A
Mathematical Approach Predicting the Number of Events in Different Tumors.
Pathology & Oncology Research 14: 199–204.
23. Yashin AI, Akushevich I, Arbeev K, Akushevich L, Kulminski A, et al. (2009)
Studying health histories of cancer: A new model connecting cancer incidence
and survival. Mathematical Biosciences 218: 88–97.
24. Moolgavkar SH, Meza R, Turim J (2009) Pleural and peritoneal mesotheliomas
in SEER: age effects and temporal trends, 1973–2005. Cancer Causes and
Control 20: 935–944.
25. Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, Lyerly HK (2011)
Breast cancer as heterogeneous disease: contributing factors and carcinogenesis
mechanisms. Breast Cancer Research and Treatment 128: 483–493.
26. Calabrese P, Mecklin JP, Jarvinen HJ, Aaltonen LA, Tavare S, et al. (2005)
Numbers of mutations to different types of colorectal cancer. BMC Cancer 5:
126.
27. Slaughter DP, Southwick HW, Smejkal W (1953) ‘‘Field cancerization’’ in oral
stratified squamous epithelium. Clinical implications of multicentric origin.
Cancer 6: 963–968.
28. Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, et al. (2012) Differences
Between Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Are
Adenocarcinoma and Squamous Cell Carcinoma Prognostically Equal?
Japanese Journal of Clinical Oncology 42: 189–195.
29. Kondo M, Dono K, Sakon M, Shimizu J, Nagano H, et al. (2002)
Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology 49:
1230–1234.
30. Peterson P, Park K, Fossella F, Gatzemeier U, John W, et al. (2007) Is
pemetrexed more effective in adenocarcinoma and large cell lung cancer than in
squamous cell carcinoma? A retrospective analysis of a phase III trial of
pemetrexed vs docetaxel in previously treated patients with advanced non-small
cell lung cancer (NSCLC): P2–328. Journal of Thoracic Oncology 2: S851.
31. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, et al. (2010) Optimal
immunohistochemical markers for distinguishing lung adenocarcinomas from
squamous cell carcinomas in small tumor samples. Am J Surg Pathol 34:
1805–1811.
32. Areses K, Anido U, Ruibal A, Abdulkader I, Gude F, et al. (2010) Biologic
differences between squamous cell carcinomas and denocarcinomas of the lung
demonstrated by tissue arrays: Interest for the 18F-FDG-PET. J Clin Oncol 28.
33. Lindstrom AK, Tot T, Stendahl U, Syrjanen S, Syrjanen K, et al. (2009)
Discrepancies in expression and prognostic value of tumor markers in
adenocarcinoma and squamous cell carcinoma in cervical cancer. Anticancer
Res 29: 2577–2578.
34. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG (2009) An
embryonic stem cell-like signature identifies poorly differentiated lung
adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 15:
6386–6390.
35. Schottenfeld D, Beebe-Dimmer JL (2006) Multiple Primary Cancers. In:
Schottenfeld D, Fraumeni JFJ, eds. Cancer Epidemiology and Prevention.
Oxford: University Press.
36. Cook GB (1966) A comparison of single and multiple primary cancers. Cancer
19: 959–966.
Modeling Human Carcinogenesis across Cancer Sites
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e3743037. Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics,
trends, and multiple primary cancer analyses from the Surveillance, Epidemi-
ology, and End Results (SEER) Program. The Oncologist 12: 20.
38. Okarmoto T, Ohno Y, Tsugane S, Watanabe S, Shimoyama M, et al. (1989)
Multi step Carcinogenesis Model for Adult T cell Leukemia. Cancer Science 80:
191–195.
39. Grotmol T, Bray F, Holte H, Haugen M, Kunz L, et al. (2011) Frailty Modeling
of the Bimodal Age–Incidence of Hodgkin Lymphoma in the Nordic Countries.
Cancer Epidemiology Biomarkers & Prevention 20: 1350.
40. Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, et al. (2008) Core signaling
pathways in human pancreatic cancers revealed by global genomic analyses.
Science 321: 1801.
41. Wood LD, Parsons DW, Jones S, Lin J, Sjo ¨blom T, et al. (2007) The genomic
landscapes of human breast and colorectal cancers. Science 318: 1108.
42. Meza R, Jeon J, Moolgavkar SH, Luebeck EG (2008) Age-specific incidence of
cancer: Phases, transitions, and biological implications. Proceedings of the
National Academy of Sciences of the United States of America 105:
16284–16289.
43. Armitage P, Doll R (1957) A two-stage theory of carcinogenesis in relation to the
age distribution of human cancer. British Journal of Cancer 11: 161.
44. Moolgavkar SH, Knudson AG Jr. (1981) Mutation and cancer: A model for
human carcinogenesis. Journal of the National Cancer Institute 66: 1037.
45. Tan WY (1991) Stochastic models of carcinogenesis: CRC.
46. Luebeck EG, Moolgavkar SH (2002) Multistage carcinogenesis and the
incidence of colorectal cancer. Proceedings of the National Academy of Sciences
99: 15095.
47. Little M, Wright E (2003) A stochastic carcinogenesis model incorporating
genomic instability fitted to colon cancer data. Mathematical Biosciences 183:
111–134.
48. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control.
Nature Medicine 10: 789–799.
49. Kinzler KW, Vogelstein B (1996) Lessons from Hereditary Review Colorectal
Cancer. Cell 87: 159–170.
50. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis.
Cell 61: 759–767.
51. Karayi M, Markham A (2004) Molecular biology of prostate cancer. Prostate
Cancer and Prostatic Diseases 7: 6–20.
52. Van Dyke T, Jacks T (2002) Cancer Modeling in the Modern Era:: Progress and
Challenges. Cell 108: 135–144.
53. Akushevich IV, Veremeyeva GA, Dimov GP, Ukraintseva SV, Arbeev KG, et
al. (2010) Modeling Deterministic Effects in Hematopoietic System Caused By
Chronic Exposure To Ionizing Radiation in Large Human Cohorts. Health
Physics 99: 322–329.
54. Veremeyeva G, Akushevich I, Ukraintseva S, Yashin A, Epifanova S, et al.
(2010) A new approach to individual prognostication of cancer development
under conditions of chronic radiation exposure. International Journal of Low
Radiation 7: 53–80.
55. Akushevich I, Veremeyeva G, Kravchenko J, Ukraintseva S, Arbeev K, et al.
(2012) New Stochastic Carcinogenesis Model with Covariates: an Approach
Involving Intracellular Barrier Mechanisms. Mathematical Biosciences 236:
16–30.
56. de Rijke JM, Schouten LJ, Hillen HFP, Kiemeney L, Coebergh JWW, et al.
(2000) Cancer in the very elderly Dutch population. Cancer 89: 1121–1133.
57. DePinho RA (2000) The age of cancer. Nature 408: 248–254.
58. Piantanelli L (1988) Cancer and aging - from the kinetics of biological
parameters to the kinetics of cancer incidence and mortality. Annals of the New
York Academy of Sciences 521: 99–109.
59. Smith DWE (1999) Resistance to causes of death: a study of cancer mortality
resistance in the oldest old. In: Robine JM, Forette B, Franceschi C, Allard M,
eds. Longevity: The Paradoxes of Longevity. Berlin-Heidelberg-New York:
Springer-Verlag. pp 61–71.
60. Miyaishi O, Ando F, Matsuzawa K, Kanawa R, Isobe K (2000) Cancer
incidence in old age. Mechanisms of Ageing and Development 117: 47–55.
61. Stanta G, Campagner L, Cavalieri F, Giarelli L (1997) Cancer of the oldest old -
What we have learned from autopsy studies. Clinics in Geriatric Medicine 13:
55-&.
62. Bonafe M, Valensin S, Gianni W, Marigliano V, Franceschi C (2001) The
unexpected contribution of immunosenescence to the leveling off of cancer
incidence and mortality in the oldest old. Critical Reviews in Oncology
Hematology 39: 227–233.
63. Forman D (2002) Counting cancers at the junction-a problem of routine
statistics. European Journal of Gastroenterology and Hepatology 14: 99.
64. Hazelton WD, Clements MS, Moolgavkar SH (2005) Multistage carcinogenesis
and lung cancer mortality in three cohorts. Cancer Epidemiology Biomarkers &
Prevention 14: 1171.
65. Scho ¨llnberger H, Manuguerra M, Bijwaard H, Boshuizen H, Altenburg H, et al.
(2006) Analysis of epidemiological cohort data on smoking effects and lung
cancer with a multi-stage cancer model. Carcinogenesis 27: 1432.
Modeling Human Carcinogenesis across Cancer Sites
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37430